About NXP900
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action (Type 1.5 inhibitor) which results in inhibition of both the catalytic and scaffolding functions of the SRC kinase, thereby providing a complete shutdown of the signaling pathway.
NXP900 completed a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers, supporting the phase 1b program to evaluate the safety and efficacy of NXP900 as a single agent and in combination with other anti-cancer agents
NXP900
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including SRC and YES1. NXP900 has a unique mechanism of action (Type 1.5 inhibitor) which results in inhibition of both the catalytic and scaffolding functions of the SRC kinase, thereby providing a complete shutdown of the signaling pathway. NXP900 completed a dose escalation study in patients with advanced solid tumors and a drug-drug interaction study in healthy volunteers, supporting the phase 1b program to evaluate the safety and efficacy of NXP900 as a single agent and in combination with other anti-cancer agents.
NXP800
NXP800 is an oral small molecule that exerts its biologic activity through activation of the kinase GCN2. Following the final data update from a Phase 1b clinical trial that evaluated NXP800 for the treatment of platinum resistant, ARID1a-mutated ovarian cancer that demonstrated that NXP800 was biologically active, evaluation of the feasibility of other development opportunities in which NXP800 can potentially demonstrate its anti-cancer activity more profoundly are being explored. NXP800 is also being evaluated for the treatment of cholangiocarcinoma in an investigator-sponsored clinical trial led by Mayo clinic.